Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 3:49 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1009–1032 of 1,944 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Context 2 Clear all

Conditions: Diabetes Mellitus, Type 1
Interventions: Antithymocyte Globulin, Placebo (for ATG); Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 6 Years to 34 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 20
States / cities: Orange, California • San Francisco, California • Stanford, California + 17 more

Conditions: Type 1 Diabetes Mellitus
Interventions: CoYoT1 Care, Standard Care; Behavioral · Other
Lead sponsor: Children's Hospital Los Angeles; Other
Eligibility: 16 Years to 25 Years
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Sexual Violence, Bystander Intervention
Interventions: Safe Bars active bystander training; Behavioral
Lead sponsor: RTI International; Other
Eligibility: 18 Years and older
Enrollment: 3,180 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 3
States / cities: Little Rock, Arkansas • Gainesville, Florida • Durham, North Carolina

Conditions: Substance Use Disorders, Drug Abuse, Alcohol Abuse, Posttraumatic Stress Disorder, PTSD, Recidivism, Depression
Interventions: Cognitive Processing Therapy, Control Group; Behavioral
Lead sponsor: University of Arkansas; Other
Eligibility: 18 Years and older
Enrollment: 148 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2025
U.S. locations: 2
States / cities: Osceola, Arkansas • West Memphis, Arkansas

Conditions: Anxiety
Interventions: Brief CBT for Anxiety; Behavioral
Lead sponsor: Michael E. DeBakey VA Medical Center; Federal
Eligibility: 18 Years to 99 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Osteoarthritis, Knee, Diabetes Mellitus, Type 2
Interventions: triamcinolone acetonide extended-release injectable suspension; TCA-ER, Triamcinolone Acetonide- Immediate Release;TCA-IR; Drug
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 40 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Spine Metastasis, Stereotactic Body Radiation Therapy (SBRT)
Interventions: Stereotactic Body Radiation Therapy (SBRT), Computed Tomography (CT) Simulation, Magnetic Resonance Imaging (MRI), Questionnaires; Radiation · Procedure · Behavioral
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Osteoarthritis
Interventions: Lactated Ringer, Placebo; Drug
Lead sponsor: West Virginia University; Other
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Morgantown, West Virginia

Conditions: Lung Cancer, Nonsmall Cell, Lung Cancer Stage IV, Lung Cancer Metastatic
Interventions: SLC-391, pembrolizumab; Drug · Biological
Lead sponsor: SignalChem Lifesciences Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 6
States / cities: Indianapolis, Indiana • Lafayette, Indiana • Detroit, Michigan + 3 more

Conditions: Tobacco Use Cessation, Smoking Cessation, Smoking, Tobacco Use Disorder
Interventions: Brief Intervention with NRT Initiation; Other
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 780 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Type 2 Diabetes
Interventions: Continuous Glucose Monitor and Undermyfork App, Continuous Glucose Monitor; Other
Lead sponsor: Scripps Whittier Diabetes Institute; Other
Eligibility: 18 Years to 80 Years
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Lung Cancer
Interventions: Pathways, Enhanced Usual Care; Behavioral
Lead sponsor: Laurie McLouth; Other
Eligibility: 18 Years and older
Enrollment: 234 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Sedentary Lifestyle, Physical Activity
Interventions: Physical Activity Increase (GLB-MOD), Sedentary Time Decrease (GLB-SED), 6-month delayed (DELAYED); Behavioral · Other
Lead sponsor: University of Pittsburgh; Other
Eligibility: 40 Years and older
Enrollment: 308 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Melanoma, Renal Cell Carcinoma, Non Small Cell Lung Cancer, Urothelial Carcinoma, Triple Negative Breast Cancer, HR+/HER2- Breast Cancer, Gastric Cancer
Interventions: Dose Escalation Doublet: Combination of NKTR-214 + nivolumab, Dose Expansion Doublet: Combination of NKTR-214 + nivolumab, Schedule Finding Triplet: Combination of NKTR-214+ nivolumab+ ipilimumab, Dose Expansion Triplet: Combination of NKTR-214+ nivolumab+ ipilimumab; Drug
Lead sponsor: Nektar Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 557 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 22
States / cities: La Jolla, California • Los Angeles, California • Stanford, California + 17 more

Conditions: Opioid-Related Disorders, Substance-Related Disorders
Interventions: Buprenorphine; Drug
Lead sponsor: Yale University; Other
Eligibility: 21 Years to 55 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1996 – 2005
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Obesity
Interventions: MOVE! Toward Your Goals, Enhanced Usual Care; Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years to 69 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 2
States / cities: Brooklyn, New York • New York, New York

Conditions: Pregnancy, Phenylketonuria
Interventions: Metabolic camp; Behavioral
Lead sponsor: Emory University; Other
Eligibility: 11 Years and older · Female only
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1995 – 2037
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Obesity
Interventions: Parents of Preschoolers Series, Incredible Years Series; Behavioral
Lead sponsor: University of Michigan; Other
Eligibility: 2 Years to 6 Years
Enrollment: 697 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Reproductive Health, Contraception, Sexually Transmitted Diseases
Interventions: In the Know: sexual health education; Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 13 Years to 19 Years
Enrollment: 1,260 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Fresno, California

Conditions: Sleep, Consolidation
Interventions: Targeted memory reactivation (sounds); Behavioral
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 35 Years
Enrollment: 38 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Evanston, Illinois

Conditions: Alcohol Use
Interventions: Protective Behavioral Strategies, Goal-Setting; Behavioral
Lead sponsor: University of Wyoming; Other
Eligibility: 18 Years to 25 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Laramie, Wyoming

Conditions: Parent Child Relationship, Child Social-Emotional Development, Telomere Length, Epigenetic Aging
Interventions: Promoting First Relationships in Primary Care (PFR-PC); Behavioral
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older · Female only
Enrollment: 250 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2029
U.S. locations: 1
States / cities: Raleigh, North Carolina

Conditions: Suicide
Interventions: Project Life Force Group Treatment; Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years to 89 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Advanced Haematological Malignancies
Interventions: AZD4573, Acalabrutinib; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 4
States / cities: Duarte, California • La Jolla, California • Houston, Texas + 1 more

Search by objective public record fields.

STOP-T1D Low-Dose (ATG)

CoYoT1 to California

Safer Drinking Spaces Study

Leveraging Implementation Science to Increase Access to Trauma Treatment for Incarcerated Drug Users

Brief Cognitive Behavioral Therapy for Anxiety

Knee Osteoarthritis Treatment With Zilretta vs. Kenalog in the Context of Type II Diabetes

Short Interval Postoperative Stereotactic Body Radiation Therapy (SBRT) After Surgical Intervention for Spine Metastases

Does Fluid Replacement From Preoperative NPO Status Improve Postoperative Recovery

Testing Experimental Anti-cancer Drug SLC-391 With an Approved Immunotherapy Drug, Pembrolizumab, for Advanced Lung Cancers

Treating Low-Income Smokers in the Hospital Emergency Department

Pilot RCT Evaluating Clinical Outcomes of Using Undermyfork Mobile App With Dexcom G7

Pathways, a Hope Intervention to Support Personal Goal Pursuit, Mental Health, and Quality of Life During Advanced Lung Cancer Treatment

Physical Activity and Sedentary Behavior Change; Impact on Lifestyle

A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid Tumors

Buprenorphine Maintenance Dose Schedule and Treatment Setting - 2

Improving Weight Management at the VA

Educational, Social Support, and Nutritional Interventions and Their Cumulative Effect on Pregnancy Outcomes and Quality of Life in Teen and Adult Women With Phenylketonuria

Enhancing Self Regulation as a Strategy for Obesity Prevention in Head Start Preschoolers

Personal Responsibility Education Program Innovative Strategies: Digital Initiative for Youth

The Effects of Direct Context Reactivation During Sleep on Memory

College Student Alcohol Behaviors and Strategies

The Impact of an Evidence-Based Parenting Service on Maternal Sensitivity and Infant Cellular Aging in a Population of Under-Resourced Families

Suicide Safety Planning Group Treatment: "Project Life Force"

AZD4573 in Novel Combinations With Anti-cancer Agents in Patients With Advanced Blood Cancer